CELUNasdaqPharmaceutical PreparationsFiscal year ends December 31

Celularity Inc

Financials through Q1 FY2026, quarter ended Mar 31, 2026Last filing: 10-Q on Oct 20, 2026

$1.16−0.09 (-7.20%)

Close on Oct 19, 2026

Market cap: $35.15M
P/E (TTM): –
Dividend yield: –

Debt

Borrowings on the balance sheet, Mar 31, 2026

Celularity reports no long-term debt line

Its balance sheet in XBRL does not include long-term debt, so totals and interest cost cannot be shown.

Bond issues

Individual notes and bonds outstanding

Bond-level data is not connected yet

Coupon, maturity and amount of each note will come from the debt footnote in Celularity's annual report. Trading prices and yields need FINRA TRACE data.

Where these numbers come from

Parsed from the XBRL in Celularity's annual and quarterly filings with the SEC
Per-share figures adjusted for the 1-for-10 reverse split on Jul 30, 2024
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Against peers

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is CELU.

Revenue growth-62.8% · median 3.4%

Gross margin5.3% · median 82.3%

Operating margin-321.3% · median -48.9%

Net margin-374.7% · median -38.8%

Company	Revenue	Growth
JAGX	$27.82M	+135.5%
CELU	$18.97M	-62.8%
PRQR	€15.91M	-15.9%
EMMA	$15.53M	–
ISCO	$9.51M	+3.4%
CAPR	–	–

Company

Exchange: Nasdaq
Industry: Pharmaceutical Preparations
Fiscal year ends: December 31
Employees: 115
Held by institutions: 6.8%
Auditor: EisnerAmper LLP
SEC CIK: 1752828

Advertisement
300 × 250